Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Allen

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Pediatric Blood & Cancer|August 13, 2013
Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experienceWafik Zaky, Girish Dhall, Lingyun Ji, et al.
Oncogene|September 11, 2019
Correction: LCE: an open web portal to explore gene expression and clinical associations in lung cancerLing Cai, ShinYi Lin, Luc Girard, et al.
Oncogene|December 12, 2018
LCE: an open web portal to explore gene expression and clinical associations in lung cancerLing Cai, ShinYi Lin, Luc Girard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomaScott R Plotkin, Dan G Duda, Alona Muzikansky, et al.
Neuro-Oncology|May 22, 2014
Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine gliomaUte Bartels, Johannes Wolff, Lia Gore, et al.
Neuro-Oncology|April 3, 2023
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannomaScott R Plotkin, Jeffrey Allen, Girish Dhall, et al.
Neurology|July 7, 2021
Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2Srivandana Akshintala, Nashwa Khalil, Kaleb Yohay, et al.
Journal of Neuro-Oncology|March 20, 2013
Outcome of infants and young children with newly diagnosed ependymoma treated on the "Head Start" III prospective clinical trialRajkumar Venkatramani, Lingyun Ji, Joseph Lasky, et al.
Pediatric Blood & Cancer|August 3, 2007
Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experienceJason Fangusaro, Jonathan Finlay, Richard Sposto, et al.
Pediatric Blood & Cancer|June 23, 2016
Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trialsJuan C Espinoza, Kelley Haley, Neha Patel, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Pediatric Blood & Cancer|August 13, 2013
Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experienceWafik Zaky, Girish Dhall, Lingyun Ji, et al.
Oncogene|September 11, 2019
Correction: LCE: an open web portal to explore gene expression and clinical associations in lung cancerLing Cai, ShinYi Lin, Luc Girard, et al.
Oncogene|December 12, 2018
LCE: an open web portal to explore gene expression and clinical associations in lung cancerLing Cai, ShinYi Lin, Luc Girard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomaScott R Plotkin, Dan G Duda, Alona Muzikansky, et al.
Neuro-Oncology|May 22, 2014
Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine gliomaUte Bartels, Johannes Wolff, Lia Gore, et al.
Neuro-Oncology|April 3, 2023
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannomaScott R Plotkin, Jeffrey Allen, Girish Dhall, et al.
Neurology|July 7, 2021
Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2Srivandana Akshintala, Nashwa Khalil, Kaleb Yohay, et al.
Journal of Neuro-Oncology|March 20, 2013
Outcome of infants and young children with newly diagnosed ependymoma treated on the "Head Start" III prospective clinical trialRajkumar Venkatramani, Lingyun Ji, Joseph Lasky, et al.
Pediatric Blood & Cancer|August 3, 2007
Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experienceJason Fangusaro, Jonathan Finlay, Richard Sposto, et al.
Pediatric Blood & Cancer|June 23, 2016
Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trialsJuan C Espinoza, Kelley Haley, Neha Patel, et al.
Pageof 8